Laninamivir was approved for influenza treatment in Japan in 2010 and is currently marketed under the name "Inavir" by Daiichi Sankyo. Biota Pharmaceuticals  and Daiichi Sankyo co-own Laninamivir. On 1st April 2011, BARDA awarded up to an estimated U$231m to Biota Pharmaceuticals (Formerly Biota Holdings Ltd) wholly owned subsidiary, Biota Scientific Management Pty Ltd, for the advanced development of Laninamivir in the US. 
^Hayden F (January 2009). "Developing new antiviral agents for influenza treatment: what does the future hold?". Clinical Infectious Diseases. 48. Suppl 1 (S1): S3–13. doi:10.1086/591851. PMID19067613.